...
mrk-img

Merck & Company Inc, Common Stock

MRK

NYQ

$96.31

-$2.05

(-2.08%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$249.37B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
20.6067
Volume info-icon
This is the total number of shares traded during the most recent trading day.
15.96M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
3.12%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.41
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$97.22 L
$133.74 H
$96.31

About Merck & Company Inc, Common Stock

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameMRKSectorS&P500
1-Week Return-6.42%-5.55%-0.8%
1-Month Return-13.65%-7.2%2.36%
3-Month Return-15%-7.12%7.31%
6-Month Return-26.89%-2.98%12.04%
1-Year Return-4.97%10.85%32.05%
3-Year Return15.08%6.66%26.94%
5-Year Return18.88%45.54%90.46%
10-Year Return69.75%109.88%191.06%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue46.84B41.52B48.70B59.28B60.12B[{"date":"2019-12-31","value":77.92,"profit":true},{"date":"2020-12-31","value":69.06,"profit":true},{"date":"2021-12-31","value":81.02,"profit":true},{"date":"2022-12-31","value":98.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue14.11B13.62B13.63B17.41B16.13B[{"date":"2019-12-31","value":81.05,"profit":true},{"date":"2020-12-31","value":78.21,"profit":true},{"date":"2021-12-31","value":78.26,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":92.62,"profit":true}]
Gross Profit32.73B27.90B35.08B41.87B43.99B[{"date":"2019-12-31","value":74.4,"profit":true},{"date":"2020-12-31","value":63.42,"profit":true},{"date":"2021-12-31","value":79.74,"profit":true},{"date":"2022-12-31","value":95.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin69.87%67.20%72.02%70.63%73.17%[{"date":"2019-12-31","value":95.49,"profit":true},{"date":"2020-12-31","value":91.83,"profit":true},{"date":"2021-12-31","value":98.43,"profit":true},{"date":"2022-12-31","value":96.52,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses20.49B22.35B21.88B23.59B41.03B[{"date":"2019-12-31","value":49.93,"profit":true},{"date":"2020-12-31","value":54.47,"profit":true},{"date":"2021-12-31","value":53.32,"profit":true},{"date":"2022-12-31","value":57.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income9.23B6.08B13.70B19.40B2.95B[{"date":"2019-12-31","value":47.56,"profit":true},{"date":"2020-12-31","value":31.32,"profit":true},{"date":"2021-12-31","value":70.64,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":15.23,"profit":true}]
Total Non-Operating Income/Expense1.62B(457.00M)(90.00M)(2.64B)(1.75B)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-28.24,"profit":false},{"date":"2021-12-31","value":-5.56,"profit":false},{"date":"2022-12-31","value":-163.35,"profit":false},{"date":"2023-12-31","value":-107.91,"profit":false}]
Pre-Tax Income11.46B8.79B13.88B16.44B1.89B[{"date":"2019-12-31","value":69.72,"profit":true},{"date":"2020-12-31","value":53.46,"profit":true},{"date":"2021-12-31","value":84.4,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":11.49,"profit":true}]
Income Taxes1.69B1.71B1.52B1.92B1.51B[{"date":"2019-12-31","value":87.96,"profit":true},{"date":"2020-12-31","value":89.1,"profit":true},{"date":"2021-12-31","value":79.3,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":78.83,"profit":true}]
Income After Taxes9.78B7.08B12.36B14.53B377.00M[{"date":"2019-12-31","value":67.31,"profit":true},{"date":"2020-12-31","value":48.75,"profit":true},{"date":"2021-12-31","value":85.08,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":2.6,"profit":true}]
Income From Continuous Operations9.78B7.08B12.36B14.53B4.62B[{"date":"2019-12-31","value":67.31,"profit":true},{"date":"2020-12-31","value":48.75,"profit":true},{"date":"2021-12-31","value":85.08,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":31.81,"profit":true}]
Income From Discontinued Operations704.00M704.00M704.00M--[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income9.84B7.07B13.05B14.52B365.00M[{"date":"2019-12-31","value":67.79,"profit":true},{"date":"2020-12-31","value":48.67,"profit":true},{"date":"2021-12-31","value":89.88,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":2.51,"profit":true}]
EPS (Diluted)5.195.936.267.481.50[{"date":"2019-12-31","value":69.39,"profit":true},{"date":"2020-12-31","value":79.28,"profit":true},{"date":"2021-12-31","value":83.69,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":20.05,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MRK
Cash Ratio 0.49
Current Ratio 1.36
Quick Ratio 1.15

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MRK
ROA (LTM) 10.53%
ROE (LTM) 28.33%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MRK
Debt Ratio Lower is generally better. Negative is bad. 0.57
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.43

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MRK
Trailing PE 20.58
Forward PE 10.16
P/S (TTM) 3.94
P/B 5.60
Price/FCF 29
EV/R 4.32
EV/Ebitda 14.17
PEG 0.07

FAQs

What is Merck & Company Inc share price today?

Merck & Company Inc (MRK) share price today is $96.31

Can Indians buy Merck & Company Inc shares?

Yes, Indians can buy shares of Merck & Company Inc (MRK) on Vested. To buy Merck & Company Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MRK stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Merck & Company Inc be purchased?

Yes, you can purchase fractional shares of Merck & Company Inc (MRK) via the Vested app. You can start investing in Merck & Company Inc (MRK) with a minimum investment of $1.

How to invest in Merck & Company Inc shares from India?

You can invest in shares of Merck & Company Inc (MRK) via Vested in three simple steps:

  • Click on Sign Up or Invest in MRK stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Merck & Company Inc shares
What is Merck & Company Inc 52-week high and low stock price?

The 52-week high price of Merck & Company Inc (MRK) is $133.74. The 52-week low price of Merck & Company Inc (MRK) is $97.22.

What is Merck & Company Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Merck & Company Inc (MRK) is 20.6067

What is Merck & Company Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Merck & Company Inc (MRK) is 5.60

What is Merck & Company Inc dividend yield?

The dividend yield of Merck & Company Inc (MRK) is 3.12%

What is the Market Cap of Merck & Company Inc?

The market capitalization of Merck & Company Inc (MRK) is $249.37B

What is Merck & Company Inc’s stock symbol?

The stock symbol (or ticker) of Merck & Company Inc is MRK

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top